Use of NF-κB inhibition in combination therapy for cancer
First Claim
Patent Images
1. A method of enhancing the cytotoxic effects of radiation therapy, comprising administering to a mammalian subject in need of said radiation therapy a therapeutically effective amount of NF-κ
- B inhibitor in conjunction with the administration of a dosage of the radiation therapy, whereby the cytotoxic effect of said radiation therapy is increased compared to that which would occur in the absence of NF-κ
B inhibitor;
wherein the dosage of said radiation therapy is decreased as compared to a dosage effective without administering the NF-κ
B inhibitor in conjuction with the administration of the radiation therapy,and wherein said subject is afflicted with lung, breast, prostate, brain, kidney, liver, spleen, pancreas, bone or muscle cancer, leukemia or lymphoma.
2 Assignments
0 Petitions
Accused Products
Abstract
The use of NF-κB inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described.
13 Citations
12 Claims
-
1. A method of enhancing the cytotoxic effects of radiation therapy, comprising administering to a mammalian subject in need of said radiation therapy a therapeutically effective amount of NF-κ
- B inhibitor in conjunction with the administration of a dosage of the radiation therapy, whereby the cytotoxic effect of said radiation therapy is increased compared to that which would occur in the absence of NF-κ
B inhibitor;wherein the dosage of said radiation therapy is decreased as compared to a dosage effective without administering the NF-κ
B inhibitor in conjuction with the administration of the radiation therapy,and wherein said subject is afflicted with lung, breast, prostate, brain, kidney, liver, spleen, pancreas, bone or muscle cancer, leukemia or lymphoma. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
- B inhibitor in conjunction with the administration of a dosage of the radiation therapy, whereby the cytotoxic effect of said radiation therapy is increased compared to that which would occur in the absence of NF-κ
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeUniversity of North Carolina At Chapel Hill (University of North Carolina System)
-
Original AssigneeUniversity of North Carolina At Chapel Hill (University of North Carolina System)
-
InventorsBaldwin, Albert S., Mayo, Marty W., Wang, Cun-Yu, Cusack, James C.
-
Primary Examiner(s)Kosar; Andrew D
-
Application NumberUS11/535,738Publication NumberTime in Patent Office1,301 DaysField of SearchNoneUS Class Current424/1.11CPC Class CodesA61K 2300/00 Mixtures or combinations of...A61K 31/4745 condensed with ring systems...A61K 31/70 Carbohydrates; Sugars; Deri...A61K 38/1709 from mammalsA61K 38/191 Tumor necrosis factors [TNF...
